StockData
Kamada Ltd logo

Kamada Ltd (KMDA) stock

KMDANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 11, 2026Score 5/30
$8.07−0.09 (-1.10%)

Close on Nov 18, 2026Market cap $465.53MP/E –Yield –

Kamada operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Kamada's operating income for the twelve months ending Jun 30, 2026 was $27.83M, up 10.3% year over year. For fiscal 2025 it was $26.23M, up 30.8% from the year before. The highest annual figure on record is $26.23M in fiscal 2025.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$26.23M+30.8%
FY2024Dec 31, 2024$20.05M+99.2%
FY2023Dec 31, 2023$10.06M+122.1%
FY2022Dec 31, 2022$4.53M–
FY2021Dec 31, 2021-$696.00K-103.6%
FY2020Dec 31, 2020$19.24M-15.6%
FY2019Dec 31, 2019$22.78M+18.3%
FY2018Dec 31, 2018$19.26M+158.7%
FY2017Dec 31, 2017$7.44M–
FY2016Dec 31, 2016-$5.48M–
FY2015Dec 31, 2015-$11.42M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$9.51M+34.5%
Q1 FY2026Mar 31, 2026$6.95M-10.8%
Q4 FY2025Dec 31, 2025$3.55M-30.1%
Q3 FY2025Sep 30, 2025$7.82M+47.6%
Q2 FY2025Jun 30, 2025$7.07M+25.4%
Q1 FY2025Mar 31, 2025$7.80M+93.0%
Q4 FY2024Dec 31, 2024$5.08M+82.9%
Q3 FY2024Sep 30, 2024$5.29M+21.2%
Q2 FY2024Jun 30, 2024$5.64M+114.4%
Q1 FY2024Mar 31, 2024$4.04M+1397477.9%
Q4 FY2023Dec 31, 2023$2.78M-38.7%
Q3 FY2023Sep 30, 2023$4.37M+170391.8%
Q2 FY2023Jun 30, 2023$2.63M–
Q1 FY2023Mar 31, 2023$289-99.9%
Q4 FY2022Dec 31, 2022$4.53M–
Q3 FY2022Sep 30, 2022$2.56K–
Q2 FY2022Jun 30, 2022-$2.29M-319.3%
Q1 FY2022Mar 31, 2022$246.00K-90.7%
Q4 FY2021Dec 31, 2021-$3.30M-142.5%
Q3 FY2021Sep 30, 2021-$804.00K–
Q2 FY2021Jun 30, 2021$1.05M–
Q4 FY2020Dec 31, 2020$2.65M–
Q3 FY2020Sep 30, 2020$7.76M–

More Kamada figures

See a number that looks wrong?